Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 9/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | BAZ2A | Q9UIF9 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9865678 | 0.88 | KDM4E (0.31) | ALDH1A1KDM4E | |
| SCHEMBL6196968 | 0.77 | MEN1 (0.31) | TSHRALDH1A1SMN1; SMN2TP53NPC1 | |
| SCHEMBL18723866 | 0.76 | — | — | |
| SCHEMBL14502277 | 0.69 | ALDH1A1 (0.36) | BRD4BAZ2AALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL17713649 | 0.69 | CDC7 (0.39) | BRD4ALDH1A1MAPTKDM4E | |
| SCHEMBL13021599 | 0.67 | HPGD (0.44) | TSHRALDH1A1SMN1; SMN2MAPTTP53 | |
| SCHEMBL11495444 | 0.67 | TSHR (0.37) | BRD4TSHRALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL23840301 | 0.66 | HPGD (0.44) | TSHRALDH1A1SMN1; SMN2MAPTTP53 | |
| SCHEMBL1870140 | 0.64 | MAOA (0.34) | ALDH1A1MAPTKDM4E | |
| SCHEMBL25469391 | 0.64 | TSHR (0.35) | BRD4TSHRALDH1A1SMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260034093-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | SUMITOMO PHARMA AMERICA, INC. (US) | 2026-02-05 | — | — | US | disclosed |
| US-20240358675-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | SUMITOMO PHARMA AMERICA, INC. (US) | 2024-10-31 | — | — | US | disclosed |
| CN-118165002-A | Polycyclic compounds and methods of use thereof | 桑诺维恩药品公司 | 2024-06-11 | — | — | CN | disclosed |
| EP-3252057-B1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC (US) | 2024-03-27 | — | — | EP | disclosed |
| US-20230147360-A1 | ARYLAMIDES AND METHODS OF USE THEREOF | GENZYME CORPORATION | 2023-05-11 | — | — | US | disclosed |
| US-20230147360-A1 | ARYLAMIDES AND METHODS OF USE THEREOF | GENZYME CORPORATION | 2023-05-11 | — | — | US | disclosed |
| US-20220387382-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2022-12-08 | — | — | US | disclosed |
| US-20220387382-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2022-12-08 | — | — | US | disclosed |
| US-10894033-B2 | Multicyclic compounds and methods of use thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2021-01-19 | — | — | US | disclosed |
| US-10894033-B2 | Multicyclic compounds and methods of use thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2021-01-19 | — | — | US | disclosed |
| WO-2011069063-A2 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS, INC. (US) | 2011-06-09 | — | — | WO | disclosed |
| US-20040142976-A1 | Pyridylfuran and pyridylthiophene compounds | PFIZER INC. | 2004-07-22 | — | — | US | disclosed |
| US-6696470-B2 | FOR THERAPY OF ARTHRITIS, ASTHMA, BONE RESORPTION DISEASE, CACHEXIA, CARDIOVASCULAR DISEASE, CEREBRAL MALARIA, CROHN'S DISEASE, DIABETES, FEVER OR MYALGIA DUE TO INFECTION, GOUT, GRAFT VERSUS HOST REACTION, INFLAMMATION OF ORGANS, ETC. | PFIZER INC. | 2004-02-24 | — | — | US | disclosed |
| US-20020022729-A1 | Pyridylfuran and pyridylthiophene compounds | KAWAI AKIYOSHI (JP) | 2002-02-21 | — | — | US | disclosed |
| EP-0853083-B1 | Pyridylfuran and pyridylthiophene compounds and pharmaceutical use thereof | PFIZER (US) | 2001-09-12 | — | — | EP | disclosed |
| US-6048880-A | THERAPY FOR CYTOKINE SENSITIVE DISEASES | PFIZER PHARAMACEUTICALS INC. (JP) | 2000-04-11 | — | — | US | disclosed |
| EP-0853083-A1 | Pyridylfuran and pyridylthiophene compounds and pharmaceutical use thereof | PFIZER INC. (US) | 1998-07-15 | — | — | EP | disclosed |
| US-4191830-A | HERBICIDES AND ANIMAL GROWTH REGULATORS | AMERICAN CYANAMID COMPANY (US) | 1980-03-04 | — | — | US | disclosed |
| US-4156670-A | UREAS AND THIOUREAS, HERBICIDES, ANIMAL GROWTH REGULATORS | AMERICAN CYANAMID COMPANY (US) | 1979-05-29 | — | — | US | disclosed |
| US-4036979-A | ANIMAL GROWTH RATE ACCELERATOR | AMERICAN CYANAMID COMPANY (US) | 1977-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220387382-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | GRIN2C, NLN, COMT | BRD4 632/4885TSHR 2305/4885BAZ2A 1460/4885 |
| US-20240358675-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | GRIN2C, NLN, COMT | BRD4 632/4885TSHR 2305/4885BAZ2A 1460/4885 |
| US-20230147360-A1 | ARYLAMIDES AND METHODS OF USE THEREOF | CFTR, AADAC, ARSA | BRD4 758/4885TSHR 2786/4885BAZ2A 1061/4885 |
| US-10894033-B2 | Multicyclic compounds and methods of use thereof | GRIN2C, NLN, COMT | BRD4 632/4885TSHR 2305/4885BAZ2A 1460/4885 |
| US-20040142976-A1 | Pyridylfuran and pyridylthiophene compounds | MC2R, FCGR2A, OGFR | BRD4 1515/4885TSHR 22/4885BAZ2A 656/4885 |
| US-20020022729-A1 | Pyridylfuran and pyridylthiophene compounds | MC2R, CRHR1, NR3C2 | BRD4 1419/4885TSHR 15/4885BAZ2A 963/4885 |
| US-20260034093-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | SLC6A3, SLC6A11, SLC6A13 | BRD4 3285/4885TSHR 1683/4885BAZ2A 3749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.